Lorrany Larisse Costa Rodrigues
Research Subjects
Lorrany Larisse Costa Rodrigues has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Mariana Macambira Noronha
Department of Medical Sciences, Federal University of Ceará, Fortaleza, Brazil
2 shared publicationsValbert Oliveira Costa Filho
Department of Medical Sciences, Federal University of Ceará, Fortaleza, Brazil
2 shared publicationsAna Elisa Saragossa Zafalon
1 shared publicationAndréia Cristina de Melo
Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
1 shared publicationAngela Theresa Zuffo Yabrude
Universidade Regional de Blumenau, Blumenau, Brazil
1 shared publication- Angela Theresa Zuffo Yabrude
Universidade Regional de Blumenau (FURB), Blumenau, Brazil
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Elsevier in SSRN Electronic Journal
Public-Health Impact of Delayed Access to Neoadjuvant-Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in Brazil
Background: Pembrolizumab plus chemotherapy is the standard perioperative treatment for high-risk stage II–III triple-negative breast cancer (TNBC), based on the overall survival benefit in KEYNOTE-522. In Brazil, pembrolizumab is approved but not funded by the public health system (SUS), which covers ~76% of the population. We estimated the population impact of delayed access.Materials and Methods: A nationwide counterfactual model estimated the consequences of a 10-year delay in pembrolizumab availability within SUS. The annual eligible cohort was derived from breast-cancer incidence, private-coverage data, TNBC prevalence, and the stage II–III proportion. Treatment effect used the 5-year KEYNOTE-522 update (OS 86.6% vs 81.7%; HR 0.66). Preventable deaths were computed from the absolute 5-year mortality reduction and life-years lost from restricted mean survival time, under 95%, 75%, and 50% uptake, with deterministic and probabilistic sensitivity analyses.Results: Of 73,610 annual breast-cancer cases, approximately 5,384 women were eligible within SUS. At 95% uptake, a 10-year delay was associated with 251 preventable deaths per annual cohort 2,506 preventable deaths and 5,156 life-years lost overall, corresponding totals were 1,979 deaths (75%) and 1,319 deaths (50%). Results were most sensitive to treatment effect and TNBC prevalence, and probabilistic analyses consistently supported substantial benefit.Conclusion: Delayed incorporation of perioperative pembrolizumab into SUS is expected to cause substantial avoidable deaths and life-years lost among women with high-risk early TNBC. These estimates quantify the clinical cost of delayed access and may inform health-technology-assessment and reimbursement decisions.
- 31 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPublic-Health Impact of Delayed Access to Neoadjuvant-Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in Brazil
Background: Pembrolizumab plus chemotherapy is the standard perioperative treatment for high-risk stage II–III triple-negative breast cancer (TNBC), based on the overall survival benefit in KEYNOTE-522. In Brazil, pembrolizumab is approved but not funded by the public health system (SUS), which covers ~76% of the population. We estimated the population impact of delayed access.Materials and Methods: A nationwide counterfactual model estimated the consequences of a 10-year delay in pembrolizumab availability within SUS. The annual eligible cohort was derived from breast-cancer incidence, private-coverage data, TNBC prevalence, and the stage II–III proportion. Treatment effect used the 5-year KEYNOTE-522 update (OS 86.6% vs 81.7%; HR 0.66). Preventable deaths were computed from the absolute 5-year mortality reduction and life-years lost from restricted mean survival time, under 95%, 75%, and 50% uptake, with deterministic and probabilistic sensitivity analyses.Results: Of 73,610 annual breast-cancer cases, approximately 5,384 women were eligible within SUS. At 95% uptake, a 10-year delay was associated with 251 preventable deaths per annual cohort 2,506 preventable deaths and 5,156 life-years lost overall, corresponding totals were 1,979 deaths (75%) and 1,319 deaths (50%). Results were most sensitive to treatment effect and TNBC prevalence, and probabilistic analyses consistently supported substantial benefit.Conclusion: Delayed incorporation of perioperative pembrolizumab into SUS is expected to cause substantial avoidable deaths and life-years lost among women with high-risk early TNBC. These estimates quantify the clinical cost of delayed access and may inform health-technology-assessment and reimbursement decisions.
- 17 April 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (2) , 16
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis
Purpose The development of endocrine resistance is frequent in hormone receptor-positive, HER2-negative advanced breast cancer (HR + /HER2-ABC), particularly after CDK4/6 inhibitor exposure. Next-generation oral selective estrogen receptor degraders (SERDs) have been developed to improve estrogen receptor blockade; however, randomized trials have yielded heterogeneous results with uncertain clinical benefit. Methods A PRISMA 2020 compliant systematic review and meta-analysis with PROSPERO registration was conducted. PubMed, Embase, and Cochrane CENTRAL were searched through October 2025 for phase II–III randomized trials comparing oral SERDs with standard endocrine therapy (ET) in HR + /HER2-ABC after prior ET. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and treatment-related adverse events (TRAEs). Treatment effects were pooled using random effects models with prespecified subgroup analyses by ESR1 mutation status and key clinical characteristics. Results Six randomized trials, including 2808 patients, were analyzed. Oral SERDs improved PFS versus standard ET in the overall population (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.70 to 0.89). ORR was higher with oral SERDs (odds ratio [OR] 1.67; 95% CI 1.23 to 2.28), corresponding to absolute response rates of approximately 21% versus 14%. An OS improvement was observed (HR 0.72; 95% CI 0.57 to 0.90), although follow-up was limited. Benefit was concentrated in ESR1-mutated tumors (PFS, HR 0.57; 95% CI 0.48 to 0.67) with no significant PFS advantage in ESR1 wild-type disease. Gastrointestinal adverse events were more frequent with oral SERDs compared with the control ET. Conclusions Pooled randomized evidence supports a clinically meaningful benefit of oral SERDs over standard ET after endocrine progression in HR + /HER2-ABC, with the strongest and most consistent efficacy observed in ESR1-mutated disease.
- 17 April 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (2) , 16
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis
Purpose The development of endocrine resistance is frequent in hormone receptor-positive, HER2-negative advanced breast cancer (HR + /HER2-ABC), particularly after CDK4/6 inhibitor exposure. Next-generation oral selective estrogen receptor degraders (SERDs) have been developed to improve estrogen receptor blockade; however, randomized trials have yielded heterogeneous results with uncertain clinical benefit. Methods A PRISMA 2020 compliant systematic review and meta-analysis with PROSPERO registration was conducted. PubMed, Embase, and Cochrane CENTRAL were searched through October 2025 for phase II–III randomized trials comparing oral SERDs with standard endocrine therapy (ET) in HR + /HER2-ABC after prior ET. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and treatment-related adverse events (TRAEs). Treatment effects were pooled using random effects models with prespecified subgroup analyses by ESR1 mutation status and key clinical characteristics. Results Six randomized trials, including 2808 patients, were analyzed. Oral SERDs improved PFS versus standard ET in the overall population (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.70 to 0.89). ORR was higher with oral SERDs (odds ratio [OR] 1.67; 95% CI 1.23 to 2.28), corresponding to absolute response rates of approximately 21% versus 14%. An OS improvement was observed (HR 0.72; 95% CI 0.57 to 0.90), although follow-up was limited. Benefit was concentrated in ESR1-mutated tumors (PFS, HR 0.57; 95% CI 0.48 to 0.67) with no significant PFS advantage in ESR1 wild-type disease. Gastrointestinal adverse events were more frequent with oral SERDs compared with the control ET. Conclusions Pooled randomized evidence supports a clinically meaningful benefit of oral SERDs over standard ET after endocrine progression in HR + /HER2-ABC, with the strongest and most consistent efficacy observed in ESR1-mutated disease.
- 11 February 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 40
Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-Analysis
- 11 February 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 40
Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-Analysis